Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. [electronic resource]
Producer: 20070215Description: 144-9 p. digitalISSN:- 1558-7673
- Adenocarcinoma -- drug therapy
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bridged-Ring Compounds -- adverse effects
- Disease Progression
- Estramustine -- administration & dosage
- Humans
- Male
- Middle Aged
- Neoplasms, Hormone-Dependent -- drug therapy
- Paclitaxel -- administration & dosage
- Prostate-Specific Antigen -- blood
- Prostatic Neoplasms -- drug therapy
- Survival Rate
- Taxoids -- adverse effects
- Thalidomide -- administration & dosage
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.